


(moved from page 18 of the Specification as filed)

# CLAIMS

What is claimed is:

1. Use of the hydrogenated pyrido [4,3-b] indole derivatives of the formula (I)



wherein  $R_1$  is Me, Et or  $\text{PhCH}_2$ ;

$R_2$  is H,  $\text{PhCH}_2$  or 6-Me-3-Py- $(\text{CH}_2)_2$ ;

$R_3$  is H, Me or Br;

provided that

(a) when  $---$  represents a single bond, then

$R_1 = R_3 = \text{Me}$ ;  $R_2 = \text{H}$ ; and the compound is in the form of a cis ( $\pm$ ) isomer; or

(b) when  $---$  represents a double bond, then

(i)  $R_1 = \text{Et}$  or  $\text{PhCH}_2$ ,  $R_2 = R_3 = \text{H}$ ,

(ii)  $R_1 = R_3 = \text{Me}$ ,  $R_2 = \text{PhCH}_2$ ,

(iii)  $R_1 = \text{Me}$ ,  $R_2 = 6\text{-Me-3-Py-}(\text{CH}_2)_2$ ,  $R_3 = \text{H}$ ,

(iv)  $R_1 = R_3 = \text{Me}$ ,  $R_2 = 6\text{-Me-3-Py-}(\text{CH}_2)_2$ ,

(v)  $R_1 = \text{Me}$ ,  $R_2 = \text{H}$ ,  $R_3 = \text{H}$  or Me,

(vi)  $R_1 = \text{Me}$ ,  $R_2 = \text{H}$ ,  $R_3 = \text{Br}$ ,

and salts thereof with pharmacologically acceptable acids and quaternary derivatives as the agents for the treatment of neurodegenerative diseases.